Development of HeartPrint Bioink

HeartPrint Bioink 的开发

• 批准号: 571266-2022
• 负责人: Willerth, Stephanie
• 金额: $ 1.46万
• 依托单位: University of Victoria
• 依托单位国家: 加拿大
• 项目类别: Idea to Innovation
• 财政年份: 2021
• 资助国家: 加拿大
• 起止时间: 2021-01-01 至 2022-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=729119
• 关键词: Development; HeartPrint; Bioink

3D bioprinting enables to generation of human tissue models for screening potential drug targets in a more relevant fashion compared to animal models. Animal models fail to predict the toxicity of potential drug targets on cardiovascular system, including the heart. 40% of drugs that enter clinical trials fail as a result of unexpected cardiotoxicity. Thus, a huge market exists for a bioink capable of printing human cardiac tissues that can be used to screen potential drugs for this issue. This project will upon our team's expertise in producing TissuePrint and BrainPrint to perform the research and development necessary to generate such a bioink, which we have termed "HeartPrint". HeartPrint bioink fills this important market gap and this project will further enable research and development here in Canada. This Lab to Market project will be conducted by Milena Perez - an award winning biomedical engineer at the University of Victoria - who has already published three well received, peer reviewed journal articles about using 3D bioprinting to produce stem cell-derived tissues. This project will be conducted under the guidance of Dr. Willerth - an internationally recognized expert in 3D printing and tissue engineering.

与动物模型相比，3D生物打印能够以更相关的方式生成用于筛选潜在药物靶点的人体组织模型。动物模型无法预测潜在药物靶点对心血管系统（包括心脏）的毒性。40%进入临床试验的药物由于意外的心脏毒性而失败。因此，对于能够打印人类心脏组织的生物墨水存在巨大的市场，该生物墨水可用于筛选针对该问题的潜在药物。该项目将利用我们团队在生产TissuePrint和BrainPrint方面的专业知识，进行必要的研究和开发，以产生这样一种生物墨水，我们称之为“HeartPrint”。 HeartPrint生物墨水填补了这一重要的市场空白，该项目将进一步促进加拿大的研究和开发。这个实验室到市场的项目将由Milena Perez进行，他是维多利亚大学的获奖生物医学工程师，已经发表了三篇关于使用3D生物打印生产干细胞衍生组织的广受好评的同行评审期刊文章。该项目将在国际公认的3D打印和组织工程专家Willerth博士的指导下进行。